Results 191 to 200 of about 2,022,996 (246)

Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies. [PDF]

Immune Netw
Ko D, Park SB, Nam KH, Choi JM, Lee KM.
europepmc   +1 more source

Superior in-vivo efficacy of integrated tumor neoantigen vaccination with adoptive neoantigen-reactive T-cell therapy in solid tumor. [PDF]

Transl Oncol
Liang G, Zhang B, Chen D, Chen Q, Lai L, Su Z, Ruan Q, Ruan R.   +7 more
europepmc   +1 more source

Biomarker-driven immunotherapy and adoptive cell therapy in recurrent pancreatic ductal adenocarcinoma. [PDF]

Front Med (Lausanne)
He T, Li G, Qi F.
europepmc   +1 more source

HIV-induced neoantigen immunodeficiency: a novel mechanism of immune evasion in non-small cell lung cancer and implications for next-generation immunotherapies. [PDF]

J Transl Med
Yang D, Yang L, Yang J, Wang G.
europepmc   +1 more source

Precision immuno-oncology in NSCLC: integrating ADCs, therapeutic vaccines, and adoptive cell therapies for next-generation systemic treatment. [PDF]

Front Oncol
Garg P, Singhal SS.
europepmc   +1 more source

Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy. [PDF]

Exp Mol Med
Cho S, Lee J, Lee YM, Nam JH.
europepmc   +1 more source

Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors. [PDF]

Immunity
Borden ES, Castellano D, Kantzos EA, Hughes A, Leibovit-Reiben Z, Stockard A, Choudhary A, Ma T, Li X, Mangold AR, Gutenkunst RN, LaFleur BJ, Buetow KH, Wilson MA, Hastings KT.   +14 more
europepmc   +1 more source

Artificial intelligence for translational personalized neoantigen cancer vaccine development. [PDF]

J Biomed Sci
Wei CY, Lin HC, Wu CJ, Kuo CN, Chang CM, Chou WH, Chou SP, Feng SH, Huang WC, Jiang S, Fairfax BP, Lee KY, Chang WC.   +12 more
europepmc   +1 more source